2022
Thromboelastography-Guided Therapy Enhances Patient Blood Management in Cirrhotic Patients: A Meta-analysis Based on Randomized Controlled Trials
Hartmann J, Dias J, Pivalizza E, Garcia-Tsao G. Thromboelastography-Guided Therapy Enhances Patient Blood Management in Cirrhotic Patients: A Meta-analysis Based on Randomized Controlled Trials. Seminars In Thrombosis And Hemostasis 2022 DOI: 10.1055/s-0042-1757135.Peer-Reviewed Original ResearchPatient blood managementBlood productsAdult patientsAdverse eventsBlood managementIntensive care unit stayIndividual blood productsLess blood productsBlood product useCo-primary outcomesLong-term mortalityFresh frozen plasma unitsRisk of hemorrhageRandomized Controlled TrialsRegistered Systematic ReviewUse of thromboelastographyFrozen plasma unitsBleeding eventsFFP useUnit stayProduct transfusionTerm mortalityCirrhotic patientsCoagulation statusPlatelet useSafety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites
Bajaj J, Fischer J, Yeramian P, Gavis E, Fagan A, Angeli P, Garcia-Tsao G, Adams J, Markham P. Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites. GastroHep 2022, 2022: 1-8. DOI: 10.1155/2022/5065478.Peer-Reviewed Original ResearchLarge-volume paracentesesRefractory ascitesContinuous intravenous infusionIntravenous infusionAverage steady-state plasma concentrationTreatment-related adverse eventsSteady-state plasma concentrationsML/min/Efficacy of terlipressinInfusion of terlipressinSafety/tolerabilityAdvanced liver cirrhosisPhase 2a trialVolume of ascitesVolume of distributionState plasma concentrationsHepatorenal syndromeVariceal bleedingCirrhotic patientsInpatient periodAdverse eventsLiver cirrhosisIV infusionRelated complicationsAcceptable safetyAscites and its complications
Garcia‐Tsao G. Ascites and its complications. 2022, 522-531. DOI: 10.1002/9781119600527.ch59.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCirrhotic ascitesPresence of ascitesMainstay of therapySevere liver diseaseSpontaneous bacterial peritonitisAccumulation of fluidHepatorenal syndromePeritoneal malignancyUncomplicated ascitesAbdominal ultrasonographySodium restrictionCirrhotic patientsHepatic hydrothoraxBacterial peritonitisHeart failureLiver diseaseDecompensated stageCommon causePeritoneal cavityAscitesPatientsMost cost-effective methodBacterial infectionsCirrhosisCommon typeAscites and its complications
García‐Tsao G. Ascites and its complications. 2022, 2024-2043. DOI: 10.1002/9781119600206.ch98.Peer-Reviewed Original ResearchHepatic sinusoidal pressureHepatic venous pressure gradientSerum-ascites albumin gradientAcute kidney injuryPresence of ascitesVenous pressure gradientMain pathogenic mechanismPredominance of neutrophilsSinusoidal pressureAccumulation of fluidAbdominal ultrasonographyKidney injurySodium restrictionCirrhotic patientsPortal pressureSodium retentionDecompensated stageInflammatory processPolymorphonuclear cellsPeritoneal cavityAscites albuminAscitic fluidAscitesCirrhosisPathogenic mechanismsPrognosis of hospitalized patients with cirrhosis and acute kidney disease
Wong F, Garcia‐Tsao G, Reddy KR, O'Leary JG, Kamath PS, Tandon P, Lai JC, Vargas HE, Biggins SW, Fallon MB, Thuluvath PJ, Maliakkal BJ, Subramanian R, Thacker L, Bajaj JS. Prognosis of hospitalized patients with cirrhosis and acute kidney disease. Liver International 2022, 42: 896-904. PMID: 35023264, PMCID: PMC11075740, DOI: 10.1111/liv.15154.Peer-Reviewed Original ResearchConceptsAcute kidney diseaseStage 1 AKIAKD patientsPeak ScrAKI patientsCirrhotic patientsKidney diseaseSecond infectionEnd-stage liver diseaseDecompensated cirrhotic patientsHigher hospital admissionsWorse renal dysfunctionNormal renal functionGlomerular filtration rateNorth American ConsortiumBaseline SCrRenal dysfunctionPrompt treatmentRenal functionSerum creatinineHospital admissionClinical outcomesLiver diseasePredictive factorsFiltration rate
2021
SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation
Kaplan D, Mehta R, Garcia-Tsao G, Albrecht J, Aytaman A, Baffy G, Bajaj J, Hernaez R, Hunt K, Ioannou G, Johnson K, Kanwal F, Lee T, Monto A, Pandya P, Schaubel D, Taddei T. SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. Contemporary Clinical Trials 2021, 104: 106367. PMID: 33771685, PMCID: PMC8422958, DOI: 10.1016/j.cct.2021.106367.Peer-Reviewed Original ResearchConceptsHepatic decompensationPortal hypertensionEvents of decompensationHepatic decompensation eventsLiver-related deathSignificant portal hypertensionAcceptable safety profileProspective human studiesRole of statinsChronic liver diseaseClasses of medicationsPatient-reported outcomesDevelopment of decompensationEffect of simvastatinVA Medical CenterCompensated cirrhosisDecompensation eventsStatin therapyVariceal hemorrhageCirrhotic patientsStandard therapyVascular reactivityExert pleiotropic effectsLiver diseaseRetrospective study
2019
573 – Predictive Factors for the Development of Acute-Onchronic Liver Failure in a North American Cohort of Hospitalized Cirrhotic Patients with Decompensation
Wong F, Reddy K, Tandon P, O'Leary J, Garcia-Tsao G, Lai J, Vargas H, Biggins S, Maliakkal B, Fallon M, Subramanian R, Thuluvath P, Kamath P, Thacker L, Bajaj J. 573 – Predictive Factors for the Development of Acute-Onchronic Liver Failure in a North American Cohort of Hospitalized Cirrhotic Patients with Decompensation. Gastroenterology 2019, 156: s-1205. DOI: 10.1016/s0016-5085(19)39995-0.Peer-Reviewed Original ResearchTargets to improve quality of care for patients with hepatic encephalopathy: data from a multi‐centre cohort
Bajaj JS, O’Leary J, Tandon P, Wong F, Kamath PS, Biggins SW, Garcia‐Tsao G, Lai J, Fallon MB, Thuluvath PJ, Vargas HE, Maliakkal B, Subramanian RM, Thacker LR, Reddy KR. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi‐centre cohort. Alimentary Pharmacology & Therapeutics 2019, 49: 1518-1527. PMID: 31032966, PMCID: PMC6538445, DOI: 10.1111/apt.15265.Peer-Reviewed Original ResearchConceptsQuality of careAspiration pneumoniaEnd-stage Liver Disease cohortLiver disease cohortMulti-center cohortNorth American ConsortiumLiver transplantMELD scoreCirrhotic patientsDual therapyHepatic encephalopathyPneumonia developmentReadmission analysisBetter prognosisPatient cohortTherapy patientsDisease cohortLarge cohortPatientsMedicationsCohortAmerican ConsortiumTherapyReadmissionPneumonia
2017
Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes
Wong F, O'Leary J, Reddy K, Garcia-Tsao G, Fallon M, Biggins S, Subramanian R, Thuluvath P, Kamath P, Patton H, Maliakkal B, Tandon P, Vargas H, Thacker L, Bajaj J. Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes. The American Journal Of Gastroenterology 2017, 112: 1103. PMID: 28440305, DOI: 10.1038/ajg.2017.122.Peer-Reviewed Original ResearchConceptsAcute kidney injuryBaseline serum creatinineHigher baseline serum creatinineInternational Ascites ClubSerum creatinineDelta serum creatinineAKI outcomesKidney injuryPatient outcomesDevelopment of AKIIncidence of AKIStage 1 acute kidney injuryTertiary-care hepatology centersEnd-stage liver diseaseBaseline SCr levelPeak serum creatinineMultivariate logistic regressionNorth American ConsortiumAKI episodesAKI progressionAKI riskCirrhotic inpatientsHepatology centersCirrhotic patientsSCr levels421 Nacseld Acute-on-Chronic Liver Failure (NACSELD-ACLF) Predicts 30-Day Mortality in Admitted Cirrhotic Patients
O'Leary J, Reddy K, Tandon P, Kamath P, Wong F, Garcia-Tsao G, Lai J, Biggins S, Fallon M, Subramanian R, Thuluvath P, Maliakkal B, Thacker L, Bajaj J. 421 Nacseld Acute-on-Chronic Liver Failure (NACSELD-ACLF) Predicts 30-Day Mortality in Admitted Cirrhotic Patients. Gastroenterology 2017, 152: s1056-s1057. DOI: 10.1016/s0016-5085(17)33569-2.Peer-Reviewed Original Research
2016
Sa1645 Beta-Blocker (BB) Use in Hospitalized Cirrhotic Patients With Ascites Is Associated With a Lower MELD, Less Inflammation and an Improved Survival
Bhutta A, Garcia-Tsao G, Reddy K, Tandon P, Wong F, O'Leary J, Acharya C, Banerjee D, Abraldes J, Plener I, Jones T, Shaw J, Deng Y, Ciarleglio M, Bajaj J. Sa1645 Beta-Blocker (BB) Use in Hospitalized Cirrhotic Patients With Ascites Is Associated With a Lower MELD, Less Inflammation and an Improved Survival. Gastroenterology 2016, 150: s1084-s1085. DOI: 10.1016/s0016-5085(16)33659-9.Peer-Reviewed Original ResearchImpact of Treatment of Non-bleeding Complications of Cirrhosis on the Risk of Variceal Bleeding
Augustin S, Albillos A, Ripoll C, Abraldes J, Salerno F, Moreau R, Reiberger T, Garcia-Tsao G. Impact of Treatment of Non-bleeding Complications of Cirrhosis on the Risk of Variceal Bleeding. 2016, 341-353. DOI: 10.1007/978-3-319-23018-4_34.Peer-Reviewed Original ResearchHepatic venous pressure gradientVariceal hemorrhageVariceal bleedingPortal pressureAlpha-1 adrenergic antagonistNon-bleeding complicationsVenous pressure gradientPortal blood flowClinical trial recordsImpact of treatmentDecompensated cirrhosisOral anticoagulantsRefractory ascitesCirrhotic patientsClinical decompensationCohort studyArterial pressureVasoactive drugsRandomized trialsLarge trialsCardiac outputProphylactic useAdrenergic antagonistsClinical dataBlood flowSecondary Prophylaxis in Special Patient Populations
Reiberger T, Moreau R, Ripoll C, Albillos A, Augustin S, Salerno F, Abraldes J, Garcia-Tsao G. Secondary Prophylaxis in Special Patient Populations. 2016, 317-332. DOI: 10.1007/978-3-319-23018-4_32.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSecondary prophylaxisRefractory ascitesVariceal bleedingSurvival benefitClinical nonrespondersClear precipitating eventProphylaxis of varicealBeta-blocker therapyBeta-blocker treatmentEndoscopic band ligationSpecial patient populationsAdvanced cirrhosisNSBB therapyVariceal rebleedingArterial hypotensionCirrhotic patientsFurther decompensationSerum creatinineBand ligationPatient populationProphylaxisHigh riskCurrent evidencePatientsAscitesPrevention of Variceal Rebleeding: Stratifying Risk and Individualizing Care
Albillos A, Abraldes J, Ripoll C, Reiberger T, Augustin S, Salerno F, Moreau R, Garcia-Tsao G. Prevention of Variceal Rebleeding: Stratifying Risk and Individualizing Care. 2016, 311-316. DOI: 10.1007/978-3-319-23018-4_31.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsStandard of careCombination therapyVariceal rebleedingVariceal ligationChild AChild B/C patientsChild B/CSecond-line therapyStandard combination therapyIndividual patient dataLow rebleedingVariceal bleedC patientsPortal hypertensionCirrhotic patientsLine therapyRisk stratificationTailor therapySuch therapyTherapyRebleedingPatientsPatient dataCarePreventionTHU-001 Beta-Blocker Use in Hospitalized Cirrhotic Patients with Ascites is Associated with a Lower Meld, less Inflammation and an Improved Survival
Bhutta A, Garcia-Tsao G, Reddy R, Tandon P, Wong F, O’Leary J, Acharya C, Banerjee D, Abraldes J, Plener I, Jones T, Shaw J, Deng Y, Ciarleglio M, Bajaj J. THU-001 Beta-Blocker Use in Hospitalized Cirrhotic Patients with Ascites is Associated with a Lower Meld, less Inflammation and an Improved Survival. Journal Of Hepatology 2016, 64: s245. DOI: 10.1016/s0168-8278(16)00253-1.Peer-Reviewed Original Research
2015
P0120 : The 3-month readmission rate remains unacceptably high in a large multi-center cohort of cirrhotic patients
Bajaj J, Reddy K, Garcia-Tsao G, Wong F, Fallon M, Subramanian R, Biggins S, Maliakkal B, Kamath P, Thuluvath P, Thacker L, O’leary J, behalf of NACSELD. O. P0120 : The 3-month readmission rate remains unacceptably high in a large multi-center cohort of cirrhotic patients. Journal Of Hepatology 2015, 62: s345-s346. DOI: 10.1016/s0168-8278(15)30340-8.Peer-Reviewed Original Research575 The 3-Month Readmission Rate Remains Unacceptably High in a Large Multi-Center Cohort of Cirrhotic Patients
Bajaj J, Reddy K, Garcia-Tsao G, Wong F, Fallon M, Subramanian R, Biggins S, Maliakkal B, Kamath P, Thuluvath P, Thacker L, O'Leary J. 575 The 3-Month Readmission Rate Remains Unacceptably High in a Large Multi-Center Cohort of Cirrhotic Patients. Gastroenterology 2015, 148: s-982-s-983. DOI: 10.1016/s0016-5085(15)33360-6.Peer-Reviewed Original Research591 Validation of Infection-Related Acute-on-Chronic Liver Failure (I-ACLF) Definition for 30-Day Mortality Prediction in Infected and Uninfected Hospitalized Cirrhotic Patients
O'Leary J, Reddy K, Garcia-Tsao G, Biggins S, Wong F, Fallon M, Subramanian R, Kamath P, Thuluvath P, Maliakkal B, Patton H, Tandon P, Thacker L, Bajaj J. 591 Validation of Infection-Related Acute-on-Chronic Liver Failure (I-ACLF) Definition for 30-Day Mortality Prediction in Infected and Uninfected Hospitalized Cirrhotic Patients. Gastroenterology 2015, 148: s-988. DOI: 10.1016/s0016-5085(15)33376-x.Peer-Reviewed Original Research
2012
Spontaneous bacterial peritonitis
Garcia‐Tsao G. Spontaneous bacterial peritonitis. 2012, 745-750. DOI: 10.1002/9781118321386.ch100.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSpontaneous bacterial peritonitisBacterial peritonitisPoor liver synthetic functionShort-term antibiotic prophylaxisCompatible clinical pictureHospitalized cirrhotic patientsLiver synthetic functionPolymorphonuclear cell countAntibiotic prophylaxisDiagnostic paracentesisIntravenous antibioticsOral norfloxacinSecondary prophylaxisGastrointestinal bleedGastrointestinal hemorrhageLiver transplantationRenal dysfunctionAlbumin therapyCirrhotic patientsAcute infectionImportant complicationClinical pictureCommon infectionsActive infectionPatients
2011
Spontaneous Bacterial Peritonitis – Prophylaxis and Treatment
Wiest R, Garcia-Tsao G. Spontaneous Bacterial Peritonitis – Prophylaxis and Treatment. Frontiers Of Gastrointestinal Research 2011, 28: 65-82. DOI: 10.1159/000318963.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSpontaneous bacterial peritonitisAntibiotic prophylaxisHistory of SBPSpontaneous bacterial peritonitis prophylaxisLong-term antibiotic treatmentPrompt effective therapyPrognosis of patientsIdentification of patientsSevere bacterial infectionsLife-threatening infectionsSpontaneous bacteremiaGastrointestinal hemorrhageCirrhotic patientsBacterial peritonitisTreatment failureAntibiotic treatmentClinical trialsCurrent guidelinesEffective therapyFirst episodeHigh riskProphylaxisPatientsBacterial infectionsSpontaneous infection